Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)
Journal Paper/Review - Jun 28, 2017
Untch Michael, Luftner Diana, Möbus Volker, Müller Volkmar, Rody Achim, Sinn Peter, Thill Marc, Thomssen Christoph, Harbeck Nadia, Kühn Thorsten, Janni Wolfgang, Gerber Bernd, Huober Jens, Jackisch Christian, Schneeweiss Andreas, Brucker Sara Y, Dall Peter, Denkert Carsten, Fasching Peter A, Fehm Tanja, Liedtke Cornelia
The St. Gallen International Consensus Conference on the treatment of patients with primary breast cancer has been held regularly (every second year in the last six years) for more than 30 years. This year, the findings of the International St. Gallen Consensus Panel and their implications for clinical practice were again discussed by a German working group of leading breast cancer specialists. Five of the breast cancer specialists from Germany were also members of this year's St. Gallen panel. A comparison between the St. Gallen recommendations and the annually updated treatment guidelines of the Gynecologic Oncology Group (AGO 2017) and the S3-guideline agreed upon in 2017 is useful. The recommendations of the St. Gallen panel represent an international cross-section of opinions of experts from different countries and different disciplines, while the S3-guideline and AGO guidelines are evidence-based. The motto of this year's 15th St. Gallen Conference was "Escalating and De-Escalating". The rationale behind this concept was to promote more individualized treatment and thereby reduce overtreatment as well as undertreatment.